MMP2, matrix metallopeptidase 2, 4313

N. diseases: 1021; N. variants: 43
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Increased TRPM7 expression was associated with enhanced SOX2, KLF4, and CD133, Hsp90α, uPA, and MMP2 expression in lung cancer cells. 30477473 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Quercetin metabolites inhibit MMP-2 expression in A549 lung cancer cells by PPAR-γ associated mechanisms. 27260467 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE And the lung cancer metastasis factors (MMP-2, MMP-9, VEGF, and CXCR4) were decreased in miR-451 group by Western blot. 25150396 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE These results suggested that PFIO could suppress the invasion and migration of human lung carcinoma by reducing the expression levels and activity of MMP-2 and MMP-9 via suppression of MAPKs, PI3K/AKT, and NF-κB signaling pathways. 25270791 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE We also showed that HMGB1 promoted lung cancer invasion and metastasis by upregulating the expression and activity of MMP-2 in an NF-<i>κ</i>B-dependent manner. 29850505 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Transcriptional analysis also revealed that lnc-MMP2-2 was highly enriched in TGF-β-mediated exosomes and might function by increasing the expression of matrix metalloproteinase (MMP)2 through its enhancer activity, with ectopic expression and silencing of lnc-MMP2-2 affecting lung cancer invasion and vascular permeability. 30256540 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE The levels of latent and active forms of MMP-2 in lung cancer samples were, correspondingly, 3.8- and 17-fold higher than in lung parenchyma. 11935310 2002
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Moreover, the decrease of MMP-2/-9 expression on lung cancer cell lines was associated with AQP1-siRNA doses. 26151179 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE MMP-2(1306C-->T) (OR, 0.53; 95% CI, 0.40-0.72; p < 0.0001) and 735(C-->T) (OR, 0.65; 95% CI, 0.53-0.79; p < 0.0001) were significantly associated with protection against lung cancer. 19507256 2009
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Subgroup by study design, ethnicity and testing methods all further identified the prognostic value of MMP2 expression in lung cancer. 22718017 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE TOB1 also regulates the gelatinase activity of MMP2 and MMP9 in lung cancer cells. 22158108 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities. 29565268 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE According to previous findings, matrix metalloproteinase-2 (MMP-2) is closely correlated with metastatic potential in lung cancer. 22082235 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE Decreases in the MMP-2 (-735) polymorphism GG genotype and increases in the MMP-13 (A77G) polymorphism AG and GG genotypes increase the risk for lung cancer. 23465389 2013
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Finally, we demonstrated that Capn4 enhanced the invasion ability of lung cancer cells by upregulating the expression of matrix metalloproteinase 2. 25636510 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE The positive expression of p53 and MMP-2 in lung cancer tissues before chemotherapy was 76.25 and 71.25%, respectively, and were reduced to 27.50 and 23.75%, respectively, after chemotherapy. 30214563 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE CONCLUSIONS The putative mechanism behind the metastasis-limiting effects of DHC may involve the suppression of Akt/GSK-3β and inhibition of MMP-2 and MMP-9 in lung cancer cells. 30388099 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE A higher MMP-2 activity was detected in lung cancer group in comparison with benign and control groups. 24415566 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE These observations indicated that naringenin inhibited the migration of lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities. 28352360 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE MMP2 genotypes and haplotypes were determined in 770 cases and 777 controls and the associations with risk of lung cancer were estimated by logistic regression. 15731163 2005
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE In this work, we report a facile approach of the fabrication of gold nanostars (GNS) attached with matrix metalloproteinases (MMP2) polypeptides (Ac-GPLGIAGQ) and IR-780 iodide through bovine serum albumin (BSA) for targeted dual-modal photoacoustic (PA)/near-infrared (NIR) fluorescence imaging and enhanced photothermal therapy (PTT)/photodynamic therapy (PDT) for lung cancer. 30851455 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Finally, we claimed that determining of MMP-2 enzyme level can be used as a marker in lung cancer. 20845079 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE The results showed that under dominant genetic model, MMP2 -1306 T was associated with lower susceptibility to lung cancer [odds ratio (OR) = 0.50, 95% confidence interval (CI) 0.43-0.59, P(heterogeneity) = 0.147, I(2) = 44.1%], head and neck cancer (OR = 0.53, 95% CI 0.41-0.69, P(heterogeneity) = 0.974, I(2) = 0.0%) and oesophageal cancer (OR = 0.67, 95% CI 0.55-0.80, P(heterogeneity) = 0.593, I(2) = 0.0%); MMP2-735T was associated with lower risk in lung cancer (OR = 0.65, 95%CI 0.53-0.79, P(heterogeneity) = 0.42, I(2) = 0.0%) and oesophageal cancer (OR = 0.84, 95% CI 0.70-0.99, P(heterogeneity) = 0.206, I(2) = 37.4%); MMP7 -181 AG and GG genotype carriers had an increased gastric cancer risk (OR = 1.90, 95% CI 1.43-2.51, P(heterogeneity) = 0.992, I(2) = 0.0%) and MMP9 -1562 C>T was not associated with cancer risk in the whole group analysis (OR = 0.99, 95% CI 0.91-1.08, P(heterogeneity) = 0.419, I(2) = 3.0%) and subgroup analyses. 20360147 2010
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Mechanistically, linc00858 acted as a competitive endogenous RNA to sponged miR-3182 and regulate MMP2 in lung cancer. 31131637 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Measurement of MMP-2 and TIMP-2 in BALF might be helpful for differential diagnosis of primary lung cancer. 29113325 2017